Symmetric Dimethylarginine As a Proinflammatory Agent in Chronic Kidney Disease
Overview
Authors
Affiliations
Background & Objectives: Chronic kidney disease (CKD) is characterized by chronic inflammation, considered a nontraditional risk factor for cardiovascular disease, the major cause of death in CKD. Symmetric dimethylarginine (SDMA) was recently demonstrated to induce reactive oxygen species in monocytes. The present study further investigates the inflammatory character of SDMA compared with its structural counterpart asymmetric dimethylarginine (ADMA).
Design, Setting, Participants, & Measurements: In vitro, the effect of SDMA on intracellular monocytic expression of IL-6 and TNF-α was studied followed by an evaluation of nuclear factor (NF)-κB activation. Additionally, an association of SDMA with inflammatory parameters in consecutive stages of CKD was evaluated in vivo.
Results: Monocytes incubated with SDMA showed increased IL-6 and TNF-α expression and a rise in active NF-κB. N-acetylcysteine abrogated both these effects. No significant effects were observed with ADMA. In vivo, 142 patients (67 ± 12 years) at different stages of CKD showed an inverse association between serum SDMA and ADMA and renal function. Correlations between SDMA and IL-6, TNF-α, and albumin were more significant than for ADMA, while multiple regression analysis only retained TNF-α at a high significance for SDMA (P < 0.0001). In receiver operating characteristic analysis for inflammation, defined as an IL-6 level above 2.97 pg/ml (median), the discriminative power of SDMA (area under the curve [AUC]: 0.69 ± 0.05) directly followed that of C-reactive protein (AUC: 0.82 ± 0.04) and albumin (AUC: 0.72 ± 0.05; for all, P < 0.0001) and preceded that of ADMA (P = 0.002).
Conclusions: The present study shows that SDMA is involved in the inflammatory process of CKD, activating NF-κB and resulting in enhanced expression of IL-6 and TNF-α, which is corroborated by the clinical data pointing to an in vivo association of SDMA with inflammatory markers in CKD at different stages.
Sari M, Akin F, Yazar A, Kilic A, Akcan O, Akkus A Eur J Pediatr. 2025; 184(4):242.
PMID: 40072664 PMC: 11903618. DOI: 10.1007/s00431-025-06079-8.
Association of Serum Symmetric Dimethylarginine Concentrations and Inflammation in Cats.
Cattaneo G, Kingsbury E, McCallum K, Williams T J Vet Intern Med. 2025; 39(2):e70030.
PMID: 40008808 PMC: 11863204. DOI: 10.1111/jvim.70030.
Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction.
Zhu X, Li X, Zhu L, Tong Z, Xu X Cardiovasc Ther. 2025; 2024:6231184.
PMID: 39742017 PMC: 11554417. DOI: 10.1155/2024/6231184.
SDMA as a marker and mediator in cerebrovascular disease.
Riddell A, Flynn A, Bergugnat H, Dowsett L, Miller A Clin Sci (Lond). 2024; 138(20):1305-1323.
PMID: 39391895 PMC: 11479986. DOI: 10.1042/CS20241021.
Chronic kidney diseases and inflammation research: a bibliometric analysis.
Wang H, Chen Y, Gou Y, Yang D, Xiong L Front Med (Lausanne). 2024; 11:1388665.
PMID: 39371339 PMC: 11449749. DOI: 10.3389/fmed.2024.1388665.